Market Access/ News/ News FDA sets April date for verdict on Incyte’s vitiligo drug Phil Taylor dermatology, fda, Incyte, Opzelura, regulatory, vitiligo 0 Comment Incyte could be a few month away from a second FDA approval for its Opzelura cream that would Share X FDA sets April date for verdict on Incyte’s vitiligo drug https://pharmaphorum.com/news/fda-sets-april-date-for-verdict-on-incytes-vitiligo-drug/
News/ News/ R&D Incyte preps second filing for ruxolitinib cream after vitiligo trial win Richard Staines dermatology, Incyte, ruxolitinib, vitiligo 0 Comment Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can Share X Incyte preps second filing for ruxolitinib cream after vitiligo trial win https://pharmaphorum.com/news/incyte-preps-second-filing-for-ruxolitinib-cream-after-vitiligo-trial-win/
dermatology, fda, Incyte, Opzelura, regulatory, vitiligo
0 Comment
